Glyn Stacey

Glyn Stacey’s background is in microbiology (Public Health Service, UK) and cancer research (University of Southampton) and he later progressed to work on the development of cell-derived products and cell-based assays at the Centre for Microbiology and Research, Porton Down, UK, where he established the Cell Development Group developing cell culture scale up systems and cell-based assays. In 1998 he moved to the National Institute for Biological Standards and Control (NIBSC-MHRA, UK) where he set up a new cell biology division working on safety of cell substrates used for vaccine manufacture and establishment of genetic reference materials. In 2002, he won a UK national grant award to initiate the UK Stem Cell Bank to provide a source of ethically suitable and quality controlled human embryonic stem cell lines for research and clinical use. In 2007 he also initiated the International Stem Cell Banking Initiative (www.iscbi.org) which brings together pluripotent cell banks from around the world to discuss best practice. Glyn has been a principal investigator in numerous European Commission funded research programmes, scientific advisory boards, national health advisory committees and was a member of the Horizon Scanning and Research Programme boards of the UK regulatory body (MHRA). Glyn has also been involved in writing standards for cell culture applications in laboratory testing (OECD, 2018), cell-based manufacture of biotherapeutics and vaccines (WHO, 2010) and regenerative medicines (UK Department of Health, 2014). Glyn currently provides assistance to a number of government organisations and foundations and is the International Director for the International Stem Cell Bank-Beijing, which is developing hESC lines for clinical trials and has 7 clinical studies registered on clinicaltrials.gov.